NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $0.79 -0.07 (-8.12%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About DBV Technologies Stock (NASDAQ:DBVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DBV Technologies alerts:Sign Up Key Stats Today's Range$0.79▼$0.8650-Day Range$0.66▼$0.9552-Week Range$0.50▼$2.17Volume376,612 shsAverage Volume236,580 shsMarket Capitalization$76.42 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingHold Company OverviewDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… DBV Technologies Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreDBVT MarketRank™: DBV Technologies scored higher than 63% of companies evaluated by MarketBeat, and ranked 442nd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingDBV Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDBV Technologies has only been the subject of 2 research reports in the past 90 days.Read more about DBV Technologies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($1.43) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.35% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 4.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.35% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 4.13%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.61 News SentimentDBV Technologies has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for DBV Technologies this week, compared to 2 articles on an average week.Search Interest1 people have searched for DBVT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,749.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Stock News HeadlinesDBV Technologies rating suspended at Goldman SachsOctober 25, 2024 | markets.businessinsider.comDBV Technologies Reports Positive Regulatory Updates for Viaskin Peanut PatchOctober 24, 2024 | americanbankingnews.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.October 29, 2024 | Porter & Company (Ad)French Biotech Stock Soars On Regulatory UpdatesOctober 24, 2024 | msn.comDBV Technologies price target raised to $7 from $5 at H.C. WainwrightOctober 24, 2024 | markets.businessinsider.comDBV Tech spikes after regulatory update on lead assetOctober 24, 2024 | seekingalpha.comPenny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval PathwayOctober 24, 2024 | msn.comDBV Technologies Rally 47% Following Positive Updates for Peanut Allergy PatchOctober 22, 2024 | marketwatch.comSee More Headlines DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $1.9056 on January 1st, 2024. Since then, DBVT stock has decreased by 58.4% and is now trading at $0.7920. View the best growth stocks for 2024 here. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) announced its quarterly earnings data on Tuesday, July, 30th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. The firm earned $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative trailing twelve-month return on equity of 74.41%. When did DBV Technologies' stock split? DBV Technologies shares reverse split on the morning of Monday, June 3rd 2024. The 1-2 reverse split was announced on Monday, June 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings7/30/2024Today10/28/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees106Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$7.00 Low Stock Price Target$2.00 Potential Upside/Downside+489.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,730,000.00 Net Margins-638.21% Pretax Margin-638.16% Return on Equity-74.41% Return on Assets-55.84% Debt Debt-to-Equity RatioN/A Current Ratio3.29 Quick Ratio3.29 Sales & Book Value Annual Sales$15.73 million Price / Sales4.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book0.55Miscellaneous Outstanding Shares96,493,000Free Float94,666,000Market Cap$76.42 million OptionableOptionable Beta0.67 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:DBVT) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.